Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis  by Hayakawa, Fumihiko & Privalsky, Martin L
A R T I C L E
Phosphorylation of PML by mitogen-activated protein kinases
plays a key role in arsenic trioxide-mediated apoptosis
Fumihiko Hayakawa and Martin L. Privalsky*
Section of Microbiology, Division of Biological Sciences, University of California at Davis, Davis, California 95616
*Correspondence: mlprivalsky@ucdavis.edu
Summary
The promyelocytic leukemia (PML) protein is a potent growth suppressor and proapototic factor, whereas aberrant fusions
of PML and retinoic acid receptor (RAR)- are causal agents in human acute promyelocytic leukemia. Arsenic trioxide
(As2O3) treatment induces apoptosis in acute promyelocytic leukemia cells through an incompletely understood mechanism.
We report here that As2O3 treatment induces phosphorylation of the PML protein through a mitogen-activated protein
(MAP) kinase pathway. Increased PML phosphorylation is associated with increased sumoylation of PML and increased
PML-mediated apoptosis. Conversely, MAP kinase cascade inhibitors, or the introduction of phosphorylation or sumoyla-
tion-defective mutations of PML, impair As2O3-mediated apoptosis by PML. We conclude that phosphorylation by MAP
kinase cascades potentiates the antiproliferative functions of PML and helps mediate the proapoptotic effects of As2O3.
Introduction activated as a transcription factor (D’Orazi et al., 2002; Fogal
et al., 2000; Guo et al., 2000; Hofmann et al., 2002). PML also
The promyelocytic leukemia (PML) protein is a RING/B box/ complexes with and modifies the activity of a wide variety of
coiled-coil (RBCC) domain polypeptide that controls critical as- additional transcription factors, coactivators, and corepressors
pects of cell cycle progression, senescence, and cell death (Mu (Salomoni and Pandolfi, 2002). Intriguingly, NBs are disrupted
et al., 1994; Salomoni and Pandolfi, 2002). Wild-type PML is a in human acute promyelocytic leukemias (APL) (Dyck et al.,
potent growth suppressor that, when overexpressed, can block 1994; Koken et al., 1994; Weis et al., 1994). The most common
cell cycle progression in a variety of tumor cell lines (Le et al., form of APL arises from a t(15;17) chromosomal translocation
1998); conversely, PML/ mouse embryo fibroblasts, spleno- that links the N-terminal region of PML to the DNA binding and
cytes, thymocytes, and keratinocytes replicate significantly hormone binding domains of retinoic acid receptor (RAR)-, a
faster than their PML/ counterparts, and are resistant to ligand-regulated transcription factor (de The, 1996). The re-
senescence mediated by activated RAS (Le et al., 1998; Liu et sulting PML-RAR fusion protein is a dominant-negative inhibi-
al., 1995; Mu et al., 1994; Salomoni and Pandolfi, 2002). PML tor of RAR activity that interferes with transcription of RAR
also plays an essential role in DNA damage- or stress-induced target genes at physiological concentrations of all-trans retinoic
apoptosis, and PML/ cells are resistant to a variety of acid (ATRA); pharmacologically elevated levels of ATRA, how-
apoptotic signals (Wang et al., 1998b). Consistent with these
ever, can overcome the PML-RAR-mediated transcriptional
properties, PML can function as a tumor suppressor, and PML
block and can induce terminal differentiation of the APL celldisruption leads to elevated incidences of papillomas, carcino-
(Grignani et al., 1993a). The ability of PML-RAR to interferemas, and T and B cell lymphomas in several mouse models of
with RAR-signaling clearly plays an important role in the patho-oncogenesis (Wang et al., 1998a, 1998b).
genesis of APL (Brown et al., 1997; Jansen et al., 1995; LavauIn normal cells, the PML protein is localized in, and essential
and Dejean, 1994). However, PML-RAR is also a dominant-for the biogenesis of, discrete subnuclear compartments vari-
negative inhibitor of the antiproliferative, proapoptotic effectsously designated as nuclear bodies (NBs), Kremer bodies, PML
of the native PML progenitor, and these antiapoptotic functionsoncogenic domains (PODs), or ND10s (Dyck et al., 1994; Ishov
of PML-RAR also contribute to the etiology of APL (de The,et al., 1999; Koken et al., 1994; Weis et al., 1994; Zhong et al.,
1996; Kawasaki et al., 2003; Rego et al., 2001). Virtually all2000). NBs are sites of protein modification, and at least one
treatments that cause reversion of APL cells also cause restora-function of PML may be to target the p53 tumor suppressor
protein to NBs where it can be acetylated, phosphorylated, and tion of the NBs, underscoring the importance of the integrity of
S I G N I F I C A N C E
The PML protein functions as a tumor suppressor in a variety of experimental model systems. Conversely, t(15;17) chromosomal
translocations result in aberrant PML expression and are associated with acute promyelocytic leukemia. Notably, these leukemias
respond to treatment with As2O3, which induces apoptosis of the leukemic cells in culture and disease remission in patients. The
mechanism by which As2O3 induces apoptosis is incompletely understood. We report here that As2O3 treatment induces a MAP
kinase cascade that phosphorylates PML and enhances the proapoptotic properties of this protein. Our work provides new insights
into the regulation of PML by phosphorylation, and new information about the therapeutic mechanisms of As2O3.
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NBs to tumor suppression (Dyck et al., 1994; Koken et al., 1994; shown). Inspection of the PML sequence in these regions re-
vealed the presence of multiple MAP kinase consensus sitesWeis et al., 1994).
Recently, it has been reported that NBs formation requires (of the sequence S/T-P; Figure 2A); we therefore introduced a
series of alanine substitutions at these sites to map the actualPML to be conjugated to SUMO (small ubiquitin-related mod-
ifier)-1 (Ishov et al., 1999; Zhong et al., 2000). SUMO-1 is an sites of ERK2 phosphorylation. Within the N-terminal domain
of PML, individual substitutions of alanine at codons 28, 36, 38,11 kDa protein that is structurally homologous to ubiquitin (Kim
et al., 2002). Sumoylation is thought to regulate the subcellular or 40 each measurably reduced phosphorylation of PML by
ERK2, whereas the alanine substitution at codon 8 did not (Fig-localization, stability, DNA binding, and/or transcriptional ability
of its target proteins such as PML, Ran GTPase activating pro- ure 2B, top panel, and quantified, bottom panel; mutations are
designated by the codon number followed by an “A”). All PMLtein (RanGAP)1, SP100, IB, heat shock transcription factor
(HSF)2, p53, and c-jun (Desterro et al., 1998; Goodson et al., constructs were assayed at comparable protein concentrations
(Figure 2B, middle panel). These results indicate that multiple2001; Gostissa et al., 1999; Mahajan et al., 1998; Matunis et
al., 1998; Muller et al., 2000, 1998; Rodriguez et al., 1999; positions within the N terminus of PML are phosphorylated by
ERK2. Consistent with this proposal, mutations incorporatingSternsdorf et al., 1997). Intriguingly, PML sumoylation is altered
in response to arsenic trioxide (As2O3), a chemotherapeutic two or more of these alanine substitutions further impaired phos-
phorylation relative to the individual mutations (Figure 2B andagent that is used clinically in the treatment of APL (Everett
et al., 1999; Muller et al., 1998). As2O3 can induce prolonged data not shown), and disruption of all four sites, 28·36·38·40A,
virtually abolished phosphorylation of the PML N-terminal do-remission even in patients with APL refractory to RA treatment
and conventional chemotherapy (Niu et al., 1999; Shen et al., main (Figure 2B). Phosphorylation of the C-terminal domain of
PML by ERK2 was measurably reduced by alanine substitutions1997). As2O3 induces both a partial differentiation and a potent
apoptosis in APL cells (Chen et al., 1997); the latter is believed at codons 527 or 530, but not at codons 505 or 518 (Figure
2C); the combined 527·530A PML mutation virtually eliminatedto play a dominant role in the As2O3-induced remission of APL
(Chen et al., 1997; Zhang et al., 2001). As2O3 treatment induces C-terminal domain phosphorylation in vitro by ERK2 (Figure 2C).
We introduced the 28·36·38·40A substitution, the 527·530Aincreased sumoylation of PML and restoration of NBs in APL
cells, and this sumoylation-associated targeting of PML into substitution, and a combined substitution of both into the full-
length PML context and designated these mutants as PML-N,NBs may be a mechanism for As2O3-induced apoptosis (Muller
et al., 1998; Zhu et al., 1997). However, the molecular basis by PML-C, and PML-NC, respectively (Figure 2A). These full-length
constructs were subjected to the same ERK2 kinase assay aswhich As2O3 triggers PML sumoylation has not been clarified.
As2O3 is known to activate a large number of signal pathways above; all proteins were assayed at comparable concentrations.
PML-N and PML-C were phosphorylated to 71% and 40% of theincluding all three mitogen-activated protein kinases (MAPKs)
pathways, i.e., extracellular-signal-regulated protein kinases wild-type level, respectively, whereas the combined PML-NC
mutant displayed only 10% of the phosphorylation observed(ERKs), c-Jun N-terminal kinases (JNKs), and p38 kinases path-
ways (Bode and Dong, 2002). We have previously demonstrated for the wild-type PML (Figure 2D). Our results indicate that the
principal sites of ERK2 phosphorylation in PML are threoninea role of MAP kinase signaling in As2O3-induced apoptosis and
differentiation of NB4 cells through the phosphorylation of si- 28 and serines 36, 38, 40, 527, and 530.
lencing mediator of retinoic acid and thyroid hormone receptor
(SMRT). SMRT is an important corepressor for PML-RAR and Arsenic trioxide causes phosphorylation of PML
through ERK1/2 in vivois essential for the dominant-negative transcriptional properties
of this fusion protein; phosphorylation of SMRT leads to its In many cell types, arsenic trioxide is a strong inducer of MAP
kinase cascade signaling (Bode and Dong, 2002; Liu et al.,dissociation from its nuclear receptor partner, including RAR
and PML-RAR, and a release from transcriptional repression 1996). We therefore examined if As2O3 could induce the phos-
phorylation of PML through ERK2. Phosphorylation of proteins(Hong et al., 2001). Here, we demonstrate that activation of
MAP kinase cascades by As2O3 has additional effects resulting can alter their mobility in SDS-PAGE, and we first tested if
phosphorylation by ERK2 caused a shift in the mobility of PML.in the phosphorylation of PML and that this enhanced phosphor-
ylation is associated with increased sumoylation in vivo and Notably, phosphorylation of wild-type PML by ERK2 in vitro
resulted in a reduction in the electrophoretic mobility of PML,may be crucial for PML-dependent apoptosis induced by As2O3.
This work provides new insights into the therapeutic mecha- phosphorylation of PML-N and PML-C resulted in a more mod-
est, but still detectable mobility shift, and incubation of PML-NCnisms of As2O3 treatment.
with ERK2 resulted in little or no change in electrophoretic mobil-
ity (Figure 3A). These results confirmed that phosphorylation ofResults
PML by ERK2 in vitro can be detected as a mobility shift in SDS-
PAGE. Next, we examined if As2O3 exposure, or coexpression ofPML is phosphorylated by the MAP kinase ERK2 in vitro
To test whether PML can be phosphorylated in response to constitutively active MEK1 (CA-MEK1, an upstream activator of
endogenous ERK1/2), resulted in phosphorylation of PMLMAP kinase signaling, we performed an in vitro kinase assay
using GST-PML as a substrate. The MAP kinase ERK2 efficiently in vivo. Either treatment caused an alteration in the mobility of
the wild-type PML protein in SDS-PAGE, and consistent withphosphorylated PML under these conditions, whereas MEKK1,
SEK1, MEK1, and p38 did not (Figure 1A). In control experi- phosphorylation, this alteration was reversed by alkaline phos-
phatase (Figures 3B and 3D). Intriguingly, although MEK1 orments, all kinases tested exhibited strong activity toward their
known substrates (Figure 1B). Use of a series of PML subdo- As2O3 signaling enhanced PML phosphorylation, a basal level
of phosphorylation of PML was detected even in the absencemains in the in vitro ERK2 kinase assay indicated that PML was
phosphorylated at both N- and C-terminal regions (data not of specific treatment, manifested as a mobility that was in-
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Figure 1. PML is phosphorylated by ERK2 in vitro
A: PML is phosphorylated in vitro. GST-PML was incubated with [-32P]ATP and the various kinases indicated. 0.5 g of active MEKK1 (MEKK1; MK), 0.1 g
of activated GST-SEK1 (S), GST-MEK1 (M), or GST-ERK2 (E), and 0.1 U of activated GST-p38 (p38) were used as kinases; 1 g of GST-PML was used as substrate.
Reaction mixtures were separated by SDS-PAGE. [-32P]-incorporation was visualized with a Phosphorimager. The positions of phosphorylated PML and
Coomassie brilliant blue (CBB)-stained PML are indicated by an asterisk and an arrow, respectively.
B: Control experiments demonstrate that all enzymes used in A were active. 0.5 g of active MEKK1, 0.1 g of activated GST-SEK1 (S), GST-MEK1 (M), or
GST-ERK2 (E), and 0.1 U of activated GST-p38 (p38) were used as kinases as in A; 0.5 g of unactivated GST-SEK1, GST-p38, or GST-ERK2, and 0.5 g of c-jun
(j) or MBP (MB) were used as substrates. Asterisks and arrows indicate phosphorylated substrates and CBB stained substrates, respectively.
creased by alkaline phosphatase treatment (Figure 3B, compare results indicate that PML phosphorylation in response to As2O3
in vivo occurs at the same sites as are phosphorylated by ERK2lanes 1 and 2). These results indicate that PML is phosphory-
lated in proliferating cells, but that inducers of MAP kinases and in vitro, and support the proposal that As2O3 induces PML phos-
phorylation through activation of ERK1/2. Of note: although theAs2O3 signaling further increase PML phosphorylation in vivo.
Consistent with As2O3 enhancing PML phosphorylation by wild-type PML is phosphorylated to some extent even in the
absence of the ectopic introduction of MEK1 or As2O3, the PML-activation of a MAP kinase cascade, As2O3 treatment increased
the phosphorylation/activation of endogenous MAP kinase in NC mutant was not (i.e., it migrated at the same mobility plus
or minus phosphatase treatment; data not shown). The basalthese cells, and this phosphorylation was blocked by the MEK1
inhibitor U0126 (Figure 3C; middle panel). Notably, U0126 also phosphorylation of PML is therefore likely due to the modifica-
tion of one or more of the ERK1/2 phosphorylation sites.blocked the change in mobility of PML in response to As2O3 in
the same cells (Figure 3C). We conclude that arsenic trioxide
activates MEK1 activity and downstream MAP kinases in CHOs, Phosphorylation of PML in response to arsenic trioxide
is associated with enhanced PML sumoylationand that the PML phosphorylation induced by As2O3 is depen-
dent on an MEK1 pathway. Given that MEK1 fails to phosphory- Sumoylation alters both the function and the subcellular distri-
bution of PML, and this modification is strongly enhanced bylate PML directly in vitro, it is likely that the As2O3-induced
phosphorylation of PML in vivo is mediated through the down- As2O3 (Muller et al., 1998). Given that ubiquitination, a related
modification, is dependent in many cases on a prior phosphory-stream MAP kinases ERK1/2. To confirm this, we examined
the effect of our phosphorylation-defective mutations of PML, lation of the protein substrate (Deshaies, 1997; Joazeiro and
Weissman, 2000), we investigated if the ability of As2O3 to inducepreviously analyzed in vitro, on As2O3-induced PML phosphory-
lation in vivo. Both the PML-N and PML-C mutants exhibited PML sumoylation might be mediated through the ability of As2O3
to induce PML phosphorylation. We set up an in vivo sumoyla-a reduced mobility shift in response to As2O3 or CA-MEK1 treat-
ment compared to wild-type PML, and the PML-NC mutant was tion system in which conjugation of a Flag-tagged SUMO to a
myc-epitope-tagged PML could be detected by Western analy-completely unresponsive to either treatment (Figure 3D). These
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Figure 2. PML is phosphorylated by ERK2 at multiple positions in both N- and C-terminal domains
A: A schematic representation of wild-type and mutant PMLs is shown. The amino acid sequences at potential ERK2 phosphorylation sites are indicated;
asterisks indicate the sites of the mutations investigated here. Serines and a threonine likely to be phosphorylated by ERK2 in vitro are underlined.
B: Mutations of potential MAP kinase sites in the PML N-terminal domain reduce phosphorylation by ERK2. Equal amounts (0.5 g) of a GST-PML (aa 1–301)
fusion construct, either wild-type or mutant, were incubated in vitro with ERK2 and were subjected to SDS-PAGE, CBB staining, and autoradiography as in
Figure 1. [32P]-incorporation into each GST-PML construct was quantified using a Phosphorimager. A representative Phosphorimager scan (top panel), the
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sis, resulting in the appearance of a novel 100 kDa PML-SUMO Notably, overexpression of PML in the CHO cells by tran-
sient transfection substantially increased As2O3-induced cellspecies containing both epitope tags (Figure 4A); as expected,
death relative to cells transfected with an empty vector (Figurethis novel species was not observed if the Flag-SUMO and
5A, compare the blue and red dashed lines). Cotransfection ofUbc9 expression vectors were omitted from the transfections
expression vectors for SUMO and Ubc9 further sensitized the(Figure 4A). Using this system, we examined the role of MEK1
PML-transfectants to As2O3-induced cell death (Figure 5A, com-pathway in the As2O3-induced sumoylation of PML. As2O3 expo-
pare the solid and dashed blue lines) whereas the proapoptoticsure resulted in a significant increase in sumoylaton that began
effects of SUMO and Ubc9 were greatly reduced in the absencean hour after arsenic exposure and reached a maximum 6 hr later
of PML (Figure 5A, red lines). These results indicate that PML(Figure 4B, top panel). The kinetics of sumoylation paralleled
potentiates cell death in response to As2O3 and suggest thatthat of ERK 1/2 activation (Figure 4B, third panel) and of PML
sumoylation further enhances the efficacy of PML in this context.phosphorylation (Figure 4B, top panel); a lighter exposure is
To test this hypothesis, we created the PML-3K mutant, whichalso provided to better visualize the change in electrophoretic
has lysine-to-arginine mutations at all three PML sumoylationmobility of PML in response to phosphorylation (Figure 4B,
sites and cannot be sumoylated (Kamitani et al., 1998a). Overex-second panel, at least two phosphorylated PML species can
pression of PML-3K in either the presence or absence of SUMO/be detected). As2O3 treatment increased sumoylation of wild-
Ubc9 had little or no effect on As2O3-induced cell death (Figuretype PML approximately 2-fold (Figure 4C). Treatment of the
5A, green lines), indicative of a requirement for PML sumoylationCHO cells with the MEK1 inhibitor U0126 abolished this As2O3-
in arsenic-mediated cell death. We next investigated the abilityinduced increase in PML sumoylation, whereas the effects of
of our phosphorylation-defective mutants of PML to mediatearsenic trioxide were mimicked by expression of the CA-MEK1
As2O3-induced cell death. The PML-N and PML-C mutants dis-construct (Figure 4C). Consistent with these observations, both
played an impaired ability to mediate cell death in response tothe PML-N and PML-C mutants displayed a reduced sumoyla-
As2O3 which was reduced still further in the combined PML-NCtion in response to either As2O3 or CA-MEK1, and the PML-NC
mutant (Figure 5B, compare the suppression of cell viability bymutant exhibited no increase in sumoylation in response to
the PML mutants, light blue, purple, and green lines, respec-either treatment (Figure 4D). Overall, our experiments indicate
tively, to the wild-type PML, dark blue line). Immunoblottingthat arsenic trioxide induces a MEK1-ERK1/2 pathway resulting
confirmed that equal levels of PML were expressed for eachin enhanced phosphorylation of PML and an associated in-
mutant (data not shown). Similarly, using U0126 to block MEK1crease in the sumoylation of this protein.
signaling reduced cell death in response to wild-type PML plus
As2O3 to the levels observed for PML-NC mutant, further sug-PML phosphorylation by ERK1/2 enhances
gesting that phosphorylation of PML plays an important role inPML-dependent apoptosis in response to arsenic trioxide
conferring cell death by As2O3 (Figure 5C, compare the dashedTo determine the biological significance of PML phosphoryla-
and solid lines).
tion, we investigated whether the As2O3-induced phosphoryla- Next, we performed TUNEL assay to determine if the de-
tion and sumoylation of PML plays a role in apoptosis. PML creased viability/increased cell death mediated by PML and
potentiates the apoptotic effects of tumor necrosis factor (TNF) As2O3 was due to apoptosis. We obtained essentially the same
 and of -irradiation (Wu et al., 2003; Yang et al., 2002), and results by TUNEL assay as for the cell death assay: apoptosis
PML might similarly enhance the proapoptotic effects of As2O3. of CHO cells in response to 3M As2O3 exposure was enhanced
We were unable to detect endogenous PML protein in our un- by ectopic expression of PML and still further enhanced by
transfected CHO cells by immunofluorescence (Figure 5E and coexpression of PML, SUMO, and Ubc9 (Figure 5D, lanes 1–4).
data not shown), using antibody that could detect human PML Both PML-N mutant and PML-C mutant transfectants exhibited
in HeLa cells and rodent PML in Rat 2 cells (Figure 5E). Similarly, a reduction in this As2O3-dependent apoptosis compared to
little or no PML mRNA was detected in untransfected CHO cells wild-type PML transfectants, and PML-NC mutant displayed
using RT-PCR and primers to PML sequences conserved in the weakest apoptotic activity in this regard (Figure 5D, lanes
human and mouse DNA databases; control PCR experiments 4–7). Furthermore, the U0126 MEK1 inhibitor inhibited apoptosis
using genomic DNA from CHO cells as template confirmed that by the wild-type PML to levels approaching those seen with
these primers were capable of efficiently recognizing hamster the phosphorylation-defective PML-NC mutant (Figure 5D, lane
PML sequences (data not shown). These determinations do not 4 versus 7, 9, and 10). MEK1 inhibitor did not affect apoptosis
demonstrate that CHO cells are truly PML negative; PML may in CHO cells transfected with empty vector (Figure 5D, lanes 1
be expressed in these cells at low levels below the limits of and 8), and these cells displayed little or no apoptosis in the
sensitivity of our assays. Nonetheless, we conclude that these absence of As2O3 (data not shown). These results indicate that
cells are suitable for examining the effects of overexpression PML phosphorylation in response to As2O3 results in increased
sumoylation and increased PML-dependent apoptosis.of ectopically introduced PML and PML mutants.
corresponding CBB-stained electrophoretogram (middle panel), and the quantitation of the [32P]-incorporation for each mutant, relative to the wild-type
PML construct (bottom panel), are presented. The average of three independent analyses and standard deviations are shown. Phosphorylated PML and
CBB-stained PML are indicated by an asterisk and an arrow, respectively.
C: Mutations of potential MAP kinase sites in the PML C-terminal domain reduce phosphorylation by ERK2. Equal amounts (0.3 g) of a GST-PML (aa 87–560)
fusion construct, either wild-type or mutant, were subject to in vitro kinase assay as in B.
D: Mutation of potential ERK2 sites in full-length PML reduces phosphorylation by ERK2. Equal amounts (0.5 g) of full-length wild-type or mutant PML were
subject to in vitro kinase assays as described in B.
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Figure 3. PML is phosphorylated in vivo by a MAP kinase cascade
A: Phosphorylation in vitro alters the electrophoretic mobility of PML. 35S-labeled PML proteins (wt or mutant) were subjected to an in vitro kinase/mobility
shift assay using unlabeled ATP in the presence () or absence (–) of activated GST-ERK2, were resolved by SDS-8% PAGE, and were visualized by
autoradiography. The mobilities of unphosphorylated (lower) and phosphorylated (higher) wild-type PML are indicated by the broken lines.
B: Arsenic trioxide or MEK1 treatment alters the electrophoretic mobility of PML in vivo. CHO cells were transfected with an expression vector for myc-
tagged PML and were cultured in the absence (–) or presence (A) of As2O3, or were cotransfected with an expression vector for CA-MEK1 in the absence
of As2O3 (M). The cells were then lysed, the lysates were immunoprecipitated with anti-myc antibody, and the immunoprecipitates were treated () or
not (–) with calf intestinal phosphatase (CIP) as indicated. The immunoprecipitates were then subjected to SDS-8% PAGE and immunoblotting with anti-
PML antibody (H238). The mobilities of phosphatase-treated PML from untreated cells (lower) and untreated PML from CA-MEK1-treated cells (higher) are
indicated by the broken lines.
C: U0126 inhibits As2O3-mediated modification of PML in vivo. Cells were transfected and treated as described in B but in the presence or absence of the
MEK1 inhibitor, U0126. Cell lysates were immunoprecipitated with anti-myc antibody, and the immunoprecipitates were subjected to SDS-8% PAGE and
immunoblotted with anti-PML antibody (H238, top panel). Whole-cell lysates were also electrophoresed and immunoblotted with anti-phospho-MAPK
antibody (middle panel) or anti-MAPK antibody (bottom panel). The mobilities of PML from untreated cells (lower) and from As2O3-treated (in the absence
of U0126) cells (higher) are indicated by the broken lines.
D: Mutations in PML amino acids subject to phosphorylation in vitro restrict modification of PML in response to As2O3 and MEK1 in vivo. Cells were treated
as described in B. PML mobility and MAP kinase activation were analyzed as described in C. The mobility of PML-NC from untreated cells (lower) and
PML-W from cells coexpressing CA-MEK1 (higher) is indicated by the broken lines.
Transiently transfected cells often express the transgene at NB formation at levels comparable to that seen for endogenous
PML expression in HeLa cells and Rat 2 cells, whereas parentalhigher than physiological levels. We therefore also established
CHO cells stably transfected with wild-type or mutant PML to CHO cells did not express PML at a detectable level (Figure 5E
and data not shown). We performed cell death assay usingexamine the apoptotic effects of PML when expressed at a
more physiological level. Stable transfectants were designated these stable transfectants and obtained essentially the same
results as those using transient transfectants: CHO-W showedwith the name of PML construct transfected; i.e., CHO-W is a
stable transfectant of PML-W. PML expression and formation an enhanced sensitivity to As2O3-induced cell death relative to
parental CHO cells (Figure 5F). Both CHO N and CHO C exhib-of PML nuclear bodies (NBs) in stable transfectants were con-
firmed by immunofluoresence with anti-PML antibody. All mu- ited a reduction in this As2O3-dependent cell death compared
to wild-type PML transfectants, and CHO NC displayed thetant or wild-type transformants expressed PML and displayed
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Figure 4. PML phosphorylation by ERK1/2 is associated with enhanced sumoylation
A: PML is sumoylated in vivo. CHO cells were transfected with a pCDNA expression vector for myc-tagged wild-type PML with or without cotransfection
of pCMV-Flag-SUMO and pCMV-Flag-Ubc9 (SUMO mix). Whole-cell lysates (W.C.L) were prepared from these cells and either the W.C.L or immunoprecipitates
using anti-PML antibody (H238) were subjected to SDS-8% PAGE followed by immunoblotting with anti-myc or anti-Flag antibody. Sumoylated and unsumoy-
lated PML are indicated by single and double arrows, respectively.
B: Kinetics of PML sumoylation and phosphorylation and ERK1/2 phosphorylation coincide. CHO cells transfected with pCDNA-myc wild-type PML, SUMO,
and Ubc9 were treated with As2O3 for the times indicated and lysed. The lysates were resolved on SDS-8% PAGE and immunoblotted with anti-myc antibody
(top panel and, in a shorter exposure, second panel), with anti-phospho-MAPK antibody (third panel), or with anti-MAPK antibody (bottom panel).
Sumoylated and unsumoylated PML are indicated by single and double arrows, respectively (top panel). PML with fast, intermediate, and slow mobilities,
representing different phosphorylation states, are indicated by an arrow, by a circled P, and by two circled Ps, respectively (second panel). The mobility
of PML with intermediate phosphorylation is indicated by the broken lines (top and second panel).
C: PML sumoylation is enhanced by As2O3 or MEK1, but inhibited by U0126 treatment. CHO cells were transfected with pCDNA-myc wild-type PML, SUMO,
and Ubc9 and were cultured in the absence () or presence (A) of As2O3, a cotransfected CA-MEK1 expression vector (M), and/or U0126 as indicated.
Cell lysates were subjected to SDS-12% PAGE, immunoblotting with anti-myc antibody, and detection with a Fluorchem 8900 Imaging System. A representative
image is shown (top panel); sumoylated and unsumoylated PML are indicated by single and double arrows, respectively. The ratio of sumoylated PML to
total PML was quantified for three independent analyses, and the average and standard deviations are presented (bottom panel).
D: PML mutations that restrict PML phosphorylation also restrict PML-sumoylation in response to arsenic trioxide and to MEK1. Wild-type and mutant PML
constructs were analyzed as in B.
weakest cell death activity in this regard (Figure 5F, compare CHO-W to levels approaching those seen with CHO NC (Figure
5G, compare the dashed and solid dark blue lines). These resultsthe suppressed cell viability of mutant transfectants, light blue,
purple, and green lines, respectively, to the wild-type transfec- on stable transformants therefore paralleled our results with the
transient transfection system.tant, dark blue line). Furthermore, U0126 inhibited cell death of
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Figure 5. PML phosphorylation at ERK sites plays an important role in As2O3-potentiated apoptosis
A: Wild-type PML enhances As2O3-induced cell death. CHO cells were transiently transfected with an empty vector, a vector expressing wild-type PML, or
a vector expressing the sumoylation-defective PML-3K mutant, and were treated with As2O3 for 24 hr at the concentrations indicated below the panel.
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PML-RAR is phosphorylated by ERK1/2 in response with or without cotreatment of MEK1 inhibitor. As anticipated,
As2O3 induced NB4 cell death, whereas the MEK1 inhibitor,to arsenic trioxide but does not enhance cell death
The ERK2 phosphorylation sites present in the PML N terminus U0126, significantly inhibited the cell death induced by As2O3,
suggesting an important role of MEK1 signaling in the therapeu-are retained in the PML-RAR fusion oncoprotein, suggest-
ing that PML-RAR might also be an ERK2 substrate. We tic treatment of APL with As2O3 (Figure 6D).
examined the in vivo phosphorylation of wild-type PML-RAR
(PR W), and of PML-RARmutants lacking the N-terminal phos- Discussion
phorylation sites found in PML (PR N, Figure 6A). Wild-type
PML-RAR exhibited a mobility shift in response to coexpres- The data presented here demonstrate that phosphorylation of
sion of CA-MEK1 (Figure 6B); this shift of PML-RAR was less PML by MAP kinases plays an important role in the control of
than that of wild-type PML, presumably due to the absence of PML-dependent apoptosis in response to As2O3 exposure. PML
the C-terminal phosphorylation sites present in the native PML is also involved in apoptosis by Fas, TNF, ceramide, and type
(Figure 6A). This shift in the mobility of wild-type PML-RAR I and II interferons; all of these stimuli activate signaling path-
was not observed in the PR N mutant, suggesting that the same ways that include MAP kinases and may operate, at least in
N-terminal amino acids identified as phosphorylation sites in part, through the ERK 1/2 phosphorylation events described
here (Cuvillier et al., 1996; David et al., 1995; Goillot et al., 1997;PML are also phosphorylated in PML-RAR. As2O3 treatment
resulted in a greater shift of wild-type PML-RAR than that seen Li et al., 2002; Vietor et al., 1993; Wang et al., 1998b). PML is
also a substrate for other kinases associated with the controlin coexpression of CA-MEK1, and the PR N mutant exhibited
a reduced, but still detectable shift in response to As2O3 (Figure of cell death, either positively or negatively. For example, PML
phosphorylation by the DNA damage checkpoint kinase hCds/6B). These results suggest that PML-RAR is phosphorylated
by the ERK1/2 kinase cascade at the N-terminal sites found in Chk2 enhances radiation-induced apoptosis (Yang et al., 2002).
Mitosis-specific phosphorylation of PML by an unknown ki-native PML, whereas As2O3 induces phosphorylation of PML-
RAR both at these N-terminal PML sites and probably at addi- nase(s) has been reported to inhibit PML sumoylation (Everett
et al., 1999).tional locations with RAR sequences.
PML-RAR has been reported to be less sensitive to sumoy- Although the ERK pathway is most often involved in cell
survival, proliferation, and differentiation (Cobb, 1999), ERK2lation than PML (Kamitani et al., 1998a, 1998b) and we could
not detect sumoylation of PML-RAR even when SUMO and activation has also been reported to mediate certain apoptotic
signals, such as those induced by Fas ligand in human neuro-Ubc9 were coexpressed (data not shown). Given that sumoyla-
tion-defective mutants of PML are impaired in mediating apo- blastoma cells, or by transforming growth factor  (TGF) in
breast carcinoma cells (Frey and Mulder, 1997; Goillot et al.,ptosis in response to As2O3 (Figure 5A), the proapoptotic effect
observed for wild-type PML might be expected to be lost in 1997). Radiation-induced apoptosis in human myeloblastic leu-
kemia cells and activation-induced cell death of mouse T cellsPML-RAR. Indeed, transient transfection of wild-type PML-
RAR into CHO cells caused little or no enhancement of cell are also known to operate through ERK2 pathways (Li et al.,
2002; Zhu et al., 1999). The contribution of ERK1/2 to apoptosisdeath in response to As2O3 (Figure 6C).
PML-RAR has been proposed to function, in part, by op- in these cases was attributed, in part, to increases in the expres-
sion of Fas ligand, Fas receptor, or jun D, but much remainsposing the proapoptotic effects of PML; acute promyelocytic
cells that express both PML and PML-RAR are therefore sub- unclear as to the mechanisms involved (Goillot et al., 1997; Li
et al., 2002; Zhu et al., 1999). Our elucidation that ERK1/2 canject to the opposing actions of both pro- and antiapoptotic
forms of PML. In this model, As2O3 would be able to overcome phosphorylate PML directly may provide additional insights into
these questions.the antiapoptotic effects of PML-RAR by phosphorylating PML
and enhancing its proapoptotic effects. We therefore performed It should be noted that even though ERK1/2 activation is
required for apoptosis induction in response to a number ofthe cell death assay using an APL-derived cell line, NB4 cells,
“SUMO mix” indicates experiments in which expression vectors for SUMO and Ubc9 were cotransfected together with the PML construct. Cell viability was
determined by trypan blue exclusion. The average and standard deviation of two independent duplicate assays are presented.
B: Mutants of PML impaired for ERK2 phosphorylation are also impaired for As2O3-induced cell death. Expression vectors for wild-type and mutant PML, or
an analogous empty vector (), were transfected with SUMO mix as indicated. Cell death was analyzed as described in A.
C: U0126 inhibits PML potentiation of As2O3-induced cell death. Expression vectors for wild-type PML or PML-NC mutant or empty vector were transfected
together with SUMO mix. Cells were then treated with As2O3 at the indicated concentrations in the presence () or absence () of U0126 for 24 hr. Cell
death was analyzed as described in A.
D: Phosphorylation of PML correlates with As2O3-induced apoptosis. Expression vectors for wild-type (W) or mutant (N, C, and NC) PML, or an analogous
empty vector (), were transfected with or without SUMO mix. Cells were then treated with 3 M As2O3 in the presence () or absence () of U0126 for
24 hr. The percentages of apoptotic cells were scored by TUNEL assay; the average and standard deviations of two independent experiments are shown.
The broken line indicates the level of TUNEL-positive cells for the empty vector control.
E: Expression of PML stably transfected into CHO cells is comparable to its endogenous expression in HeLa cells and Rat 2 cells. Cells were subjected to
immunofluoresence analysis using anti-PML antibody (5E10) with FITC-conjugated secondary antibody, or DAPI. Representative images are shown (PML,
green; DAPI, blue).
F: Wild-type PML enhances As2O3-induced cell death in stable cell transformants. Stable CHO transfectants expressing the PML alleles indicated were
subjected to a cell death assay as in A.
G: U0126 inhibits the PML potentiation of As2O3-induced cell death in stable transfectants. Stable transfectants of CHO cells were treated with As2O3 at the
indicated concentrations in the presence () or absence (–) of U0126 for 24 hr. Cell death was analyzed as in A.
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Figure 6. PML-RAR is phosphorylated by ERK1/2 but does not potentiate apoptosis in response to As2O3
A: A schematic representation of wild-type and mutant PML-RAR is shown. The DNA binding domain (DBD) and ligand binding domain (LBD) of RAR are
indicated. The vertical arrow indicates the translocation breakpoint. Asterisks indicate the position of the mutations created.
B: As2O3 and MEK1 induce a mobility shift in PML-RAR. CHO cells were treated as in Figure 3B but using myc-tagged PML-RAR (PR) instead of PML.
Changes in the electrophoretic mobility of PML-RAR in response to expression of MAP kinase or arsenic treatment were analyzed as in Figure 4B. The
mobility of PR W from untreated cells is indicated by the broken lines.
C: PML-RAR displays little or no ability to potentiate the apoptotic effects of As2O3. CHO cells were transiently transfected with an empty vector, the PML
vector (PML), or the PML-RAR vector (PR), and were subjected to cell death assay as described in Figure 5A.
D: MEK1 inhibitor inhibits the As2O3-induced cell death of NB4 cells. NB4 cells were treated with As2O3 at the indicated concentrations in the presence ()
or absence (–) of U0126 for 24 hr. Cell death was analyzed as in Figure 5A.
cell signaling pathways, ERK1/2 activation per se is typically PML phosphorylation appears to be required for PML-depen-
dent apoptosis by As2O3, additional signals from As2O3 must beinsufficient for apoptosis. This is consistent with our own obser-
vation that simple coexpression of PML and CA-MEK1 does necessary for the induction of PML-dependent apoptosis. Other
members of MAP kinase family, such as JNK and p38, arenot cause apoptosis (F.H. and M.L.P., unpublished data). Since
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activated in parallel to, and can work cooperatively with, ERK and Weissman, 2000); considering the similarity between su-
to induce apoptosis (Frey and Mulder, 1997; Goillot et al., 1997; moylation and ubiquitination, we suggest that that the phos-
Zhu et al., 1999). Although p38 cannot phosphorylate PML di- phorylation of PML in response to As2O3 may alter its interaction
rectly in vitro (Figure 1A), p38 or other MAP kinases may be with a known (or unknown) E3 ligase, regulating in turn PML
involved in As2O3-induced apoptosis by targeting proteins other sumoylation.
than PML itself. It should also be noted that parental CHO The PML-RAR fusion protein interferes with the normal
cells lacking detectable PML expression are still sensitive to functions of both PML and of RAR, and plays a crucial role in
apoptosis by As2O3, although at a much reduced level compared the pathogenesis of APL (Grignani et al., 1993b; Perez et al.,
to cells expressing PML. Either PML may be expressed in our 1993). As2O3 induces both partial differentiation and apoptosis
CHO cells at levels too low to be detected, or there may be PML- of APL-derived NB4 cells through a MEK1-MAP kinase pathway
independent apoptotic mechanisms that respond to As2O3. The (Hong et al., 2001). The prodifferentiation properties of As2O3
later possibility is not surprising, considering the variety of sig- appear to be mediated through phosphorylation and inactivation
nals activated by As2O3. Although we employed arsenic trioxide of the SMRT corepressor, and the resulting derepression of
at concentrations (1 to 10 M) that overlap the plasma levels PML-RAR target genes (Hong et al., 2001). Our new results,
achieved in the clinical treatment of APL (from 1 to over 6 M), reported here, suggest that the proapoptotic effects of As2O3
the mechanisms induced by arsenic trioxide in vivo and ex vivo in APL cells may be mediated, in part, through phosphorylation
may also differ. of PML by MAP kinase, leading to an enhanced PML sumoyla-
Sumoylation of PML is necessary for NB formation (Ishov tion and increased apoptotic function that overcomes the anti-
et al., 1999; Zhong et al., 2000), and the apoptotic effects of apoptotic properties of PML-RAR. It should be noted, how-
PML may be dependent on NB formation (see Introduction). ever, that other effects of As2O3 in APL cells have been noted,
Given our findings that PML phosphorylation by ERK1/2 is asso- including an As2O3-induced degradation of PML-RAR and of
ciated with increased PML sumoylation, this sumoylation- PML (Zhu et al., 1997, 2001). It is also likely that there are
dependent NB formation may represent one of the mechanisms additional phenotypic changes in APL cells that may enhance
by which PML phosphorylation can enhance apoptosis. This their sensitivity to arsenite-induced apoptosis independent of
hypothesis is supported by our findings that coexpression of PML and PML-RAR. More work will be required to determine
SUMO and Ubc9 enhance PML-dependent apoptosis by As2O3, the individual contributions of these different actions of As2O3that phosphorylation-defective mutants of PML exhibit defects on the proliferation, survival, and differentiation of APL cells.
in sumoylation and apoptosis in response to As2O3 treatment, In summary, our studies provide evidence for an ERK path-
and that sumoylation-impaired mutants of PML, such as PML-
way that phosphorylates PML in response to As2O3 exposure,3K and PML-RAR, are also defective for NB formation and for
and that this increase in PML phosphorylation is associatedAs2O3-mediated apoptosis. with enhanced PML sumoylation and enhanced PML-depen-Phosphatase inhibitors can inhibit PML sumoylation in vivo,
dent apoptosis. This work provides new insight into the regula-suggesting that phosphorylation can negatively regulate sumoy-
tion of PML sumoylation and establishes a novel relationshiplation in some contexts (Everett et al., 1999). The studies we
between MAP kinase signaling, PML, and As2O3-induced apo-report here, in contrast, suggest that there is a positive control
ptosis. Considering the large number of binding partners ofof PML sumoylation by phosphorylation. How might phosphory-
PML, and the key contributions of PML to the stability andlation lead to increased sumoylation? ERK-phosphorylated PML
function of the NBs, PML phosphorylation is likely to modulatemight be a better substrate for Ubc9, the E2 conjugating enzyme
multiple cell activities beyond apoptosis through regulation ofthat transfers SUMO groups onto substrate proteins. We could
recruitment or release of NBs components.not, however, demonstrate an increase in PML sumoylation in
response to ERK2 in an in vitro modification system (F.H. and
Experimental procedures
M.L.P., unpublished data), suggesting that regulation of sumoy-
lation in vivo involves additional components not present in the Antibodies, plasmids, enzymes, and cell culture
in vitro assay. Phosphorylation of PML might regulate PML traf- The sources of antibodies, plasmids, and kinases, and the cell culture condi-
fic from nucleoplasm to the nuclear matrix, where PML sumoyla- tions are detailed in the Supplemental Data at http://www.cancercell.org/
cgi/content/full/5/4/389/DC1.tion is believed to occur (Muller et al., 1998; Zhu et al., 1997).
However, rendering PML refractory to ERK1/2 phosphorylation
In vitro kinase assaysdid not affect the PML transfer to nuclear matrix induced by
GST-PML fusion proteins were expressed in Escherichia coli strain BL21As2O3 (F.H. and M.L.P., unpublished data). Another possibility and were purified by binding to, and elution from, glutathione beads (Phar-
is that phosphorylation might be required for the interaction of macia). 35S-labeled PML was prepared using the TNT transcription/transla-
PML with a SUMO E3 ligase. Although the combined actions tion system (Promega). Kinase assays were performed according to the
of an E1-activating enzyme (Aos1/Uba2) and an E2-conjugating manufacturer’s instructions or as previously described (Hong and Privalsky,
enzyme (Ubc9) are sufficient for in vitro sumoylation of a number 2000). [-32P]-incorporation into phosphorylated proteins was detected using
a STORM Imaging System (Molecular Dynamics). Molecular weight markersof targets (Gostissa et al., 1999; Mahajan et al., 1998; Muller et
analyzed in parallel were visualized by Coomassie brilliant blue staining.al., 1998; Rodriguez et al., 1999), involvement of an additional
enzyme, analogous to the E3-ligating enzymes in ubiquitination,
Transient transfections, immunoprecipitations,has been proposed for some sumoylated substrates (Seeler
and immunoblottings
and Dejean, 2001); several SUMO E3-like factors have been Cells were transiently transfected using Effectene (QIAGEN) according to
identified (Kahyo et al., 2001; Pichler et al., 2002; Sachdev et the manufacturer’s instructions and analyzed as previously described (Hong
al., 2001; Kirsh et al., 2002). Certain E3 ubiquitin ligases selec- and Privalsky, 2000). Immunoreactive proteins were detected with the ECL-
plus Western Blotting Detection System (Amersham Biosciences) using atively bind to and modify phosphorylated substrates (Joazeiro
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D’Orazi, G., Cecchinelli, B., Bruno, T., Manni, I., Higashimoto, Y., Saito, S.,Fluorchem 8900 Imaging System (Alpha Innotech) or Hyperfilm (Amersham
Gostissa, M., Coen, S., Marchetti, A., Del Sal, G., et al. (2002). Homeodo-Biosciences).
main-interacting protein kinase-2 phosphorylates p53 at Ser 46 and medi-
ates apoptosis. Nat. Cell Biol. 4, 11–19.Immunofluoresence
Cells (1 	 104 ) were seeded in a chambered coverslip cell culture system David, M., Petricoin, E., 3rd, Benjamin, C., Pine, R., Weber, M.J., and Larner,
(Nalge-Nunc) and were fixed using 1:1 methanol/acetone for 10 min A.C. (1995). Requirement for MAP kinase (ERK2) activity in interferon - and
at 20
C. After blocking in phosphate-buffered saline containing 1% BSA, interferon -stimulated gene expression through STAT proteins. Science
the fixed cells were incubated with anti-PML antibody (5E10) followed by 269, 1721–1723.
incubation with FITC-conjugated secondary antibody and DAPI. Images
de The, H. (1996). Altered retinoic acid receptors. FASEB J. 10, 955–960.were acquired using Microphoto EPI-Fl (Nikon).
Deshaies, R.J. (1997). Phosphorylation and proteolysis: partners in the regu-
In vivo phosphorylation assays lation of cell division in budding yeast. Curr. Opin. Genet. Dev. 7, 7–16.
CHO cells (5.0 	 104) were transiently transfected with appropriate PML
expression plasmids (0.25 g each) and were mock-treated, treated with Desterro, J.M., Rodriguez, M.S., and Hay, R.T. (1998). SUMO-1 modification
of IkappaBalpha inhibits NF-B activation. Mol. Cell 2, 233–239.10 M arsenic trioxide (Sigma), with 10 M U0126 (Calbiochem), or with
both for 12 hr. Total plasmid in each transfection was normalized by addition
Dyck, J.A., Maul, G.G., Miller, W.H., Jr., Chen, J.D., Kakizuka, A., and Evans,of appropriate empty vectors. PML protein in the lysates from these cells
R.M. (1994). A novel macromolecular structure is a target of the promyelo-was immunoprecipitated with anti-myc antibody. Immunoprecipitates were
cyte-retinoic acid receptor oncoprotein. Cell 76, 333–343.
subjected to dephosphorylation, where indicated, using calf intestinal alka-
line phosphatase (Hong and Privalsky, 2000). Samples were then resolved Everett, R.D., Lomonte, P., Sternsdorf, T., van Driel, R., and Orr, A. (1999).
by SDS- 8% PAGE and immunoblotting with anti-PML antibody. Cell cycle regulation of PML modification and ND10 composition. J. Cell
Sci. 112, 4581–4588.
In vivo sumoylation assays
Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K.,CHO cells (2.5 	 104 ) were transiently transfected with various expression
Pandolfi, P.P., Will, H., Schneider, C., and Del Sal, G. (2000). Regulation ofplasmids (0.125 g each) and were mock-treated, treated with 10 M As2O3,
p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19,with 10 M U0126, or with both for 12 hr. Total plasmid for each transfection
6185–6195.was normalized by the addition of empty vectors. Cells were then lysed,
and sumoylated versus unsumoylated proteins were resolved by SDS-12% Frey, R.S., and Mulder, K.M. (1997). Involvement of extracellular signal-
PAGE and by immunoblotting with anti-myc antibody. regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase
activation by transforming growth factor beta in the negative growth control
Cell death and apoptosis analysis of breast cancer cells. Cancer Res. 57, 628–633.
CHO cells (2.5 	 104 ) were transiently transfected with appropriate expres-
Goillot, E., Raingeaud, J., Ranger, A., Tepper, R.I., Davis, R.J., Harlow,sion plasmids (0.06 g each) or stably transfected with PML. NB4 cells were
E., and Sanchez, I. (1997). Mitogen-activated protein kinase-mediated Fastreated with arsenic trioxide at the indicated concentrations, with 10 M
apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA 94, 3302–3307.U0126, or with both for 24 hr. Total plasmid for each transfection was
normalized by the addition of appropriate empty vectors. Cell death was Goodson, M.L., Hong, Y., Rogers, R., Matunis, M.J., Park-Sarge, O.K., and
determined by a trypan blue exclusion assay and cell viability was calculated. Sarge, K.D. (2001). Sumo-1 modification regulates the DNA binding activity
Apoptotic cells were scored by TUNEL assay with the In Situ Cell Death of heat shock transcription factor 2, a promyelocytic leukemia nuclear body
Detection Kit (Roche Diagnostics). associated transcription factor. J. Biol. Chem. 276, 18513–18518.
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